[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 162,471,840
  • Shares Outstanding, K 1,241,570
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,370 M
  • EBITDA $ 13,130 M
  • 60-Month Beta 0.32
  • Price/Sales 5.50
  • Price/Cash Flow 12.45
  • Price/Book 6.90

Options Overview Details

View History
  • Implied Volatility 34.34% (-0.42%)
  • Historical Volatility 31.77%
  • IV Percentile 85%
  • IV Rank 68.42%
  • IV High 40.29% on 10/13/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 6) 3.77 (2.91%)
  • Put/Call Vol Ratio 0.39
  • Today's Volume 4,018
  • Volume Avg (30-Day) 7,095
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 170,452
  • Open Int (30-Day) 173,511
  • Expected Range 125.54 to 133.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-7.09
  • Number of Estimates 5
  • High Estimate $-6.99
  • Low Estimate $-7.34
  • Prior Year $2.01
  • Growth Rate Est. (year over year) -452.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
123.67 +4.56%
on 06/25/26
140.61 -8.04%
on 07/17/26
+4.15 (+3.32%)
since 06/24/26
3-Month
121.39 +6.52%
on 06/10/26
140.61 -8.04%
on 07/17/26
-1.09 (-0.84%)
since 04/24/26
52-Week
108.46 +19.22%
on 10/02/25
157.29 -17.79%
on 02/11/26
+16.11 (+14.23%)
since 07/24/25

Most Recent Stories

More News
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19...

GILD : 129.31 (-1.18%)
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern...

GILD : 129.31 (-1.18%)
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

– Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP...

MRK : 131.07 (+0.45%)
GILD : 129.31 (-1.18%)
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials – – ISL/LEN has the Potential...

MRK : 131.07 (+0.45%)
GILD : 129.31 (-1.18%)
Gilead Sciences' Quarterly Earnings Preview: What You Need to Know

Gilead Sciences will release its second-quarter earnings soon, and analysts anticipate a triple-digit profit dip.

XLV : 162.57 (+0.70%)
$SPX : 7,411.98 (+0.05%)
GILD : 129.31 (-1.18%)
3 Market-Beating Stocks with Solid Fundamentals

3 Market-Beating Stocks with Solid Fundamentals

CRC : 53.47 (-1.44%)
GILD : 129.31 (-1.18%)
URBN : 69.97 (+0.52%)
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1

GILD : 129.31 (-1.18%)
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition

VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody...

NVS : 155.01 (-0.72%)
GILD : 129.31 (-1.18%)
VRXA : 1.8000 (-3.23%)
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 37.81 (-2.60%)
AZN : 169.26 (+0.59%)
MRK : 131.07 (+0.45%)
GILD : 129.31 (-1.18%)
TEM : 42.69 (-7.22%)
GSK : 51.35 (+1.20%)
ARKK : 71.89 (-2.63%)
BMY : 62.09 (+0.94%)
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

– Trodelvy is a New Backbone Therapy and the Only Approved ADC in First-Line mTNBC Across PD-L1 Status – –...

GILD : 129.31 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 133.57
2nd Resistance Point 132.61
1st Resistance Point 130.96
Last Price 129.31
1st Support Level 128.35
2nd Support Level 127.39
3rd Support Level 125.74

See More

52-Week High 157.29
Fibonacci 61.8% 138.64
Fibonacci 50% 132.88
Last Price 129.31
Fibonacci 38.2% 127.11
52-Week Low 108.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.